Concepedia

Britton Boras

BB

16

Publications

3K

Citations

15

H-Index

2012

Active since

Affiliations

Pfizer (United States)(Current)

Utah State University

University of California San Diego

UC San Diego Health System

California Institute for Biomedical Research

Britton Boras is an author at Pfizer (United States) specializing in medicine, signal transduction, and cell biology.

ORCID

Top concepts

Publications per year

2012–2025

16

Publications

16

An oral SARS-CoV-2 M <sup>pro</sup> inhibitor clinical candidate for the treatment of COVID-19

Dafydd R. Owen, Charlotte Allerton, Annaliesa S. Anderson et al. · Science · 2021 · 1.8K citations · Full text

, , +16

Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19

Britton Boras, Rhys Jones, Brandon J. Anson et al. · Nature Communications · 2021 · 284 citations · Full text

Expanding control of the tumor cell cycle with a CDK2/4/6 inhibitor

Kevin D. Freeman‐Cook, Robert L. Hoffman, Nichol Miller et al. · Cancer Cell · 2021 · 172 citations

, , +10

Discovery of a Novel Inhibitor of Coronavirus 3CL Protease for the Potential Treatment of COVID-19

Britton Boras, Rhys Jones, Brandon J. Anson et al. · 2020 · 158 citations · Full text

Discovery of PF-06873600, a CDK2/4/6 Inhibitor for the Treatment of Cancer

Kevin D. Freeman‐Cook, Robert L. Hoffman, Douglas C. Behenna et al. · Journal of Medicinal Chemistry · 2021 · 112 citations · Full text

Rows per page

1–5 of 16